Enlivex Ltd. (Bio Blast Pharma Ltd.) Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Bio Blast Pharma Ltd. (referred to as Enlivex Ltd. in the request metadata) on September 23, 2014, for the month of September 2014. The filing serves to notify the SEC of an Extraordinary General Meeting of Shareholders scheduled for October 30, 2014.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document focuses solely on corporate governance procedures related to the upcoming shareholder vote.
Guidance, Outlook, and Risks
The filing incorporates by reference a Notice of Meeting, Proxy Statement, and Proxy Card (Exhibit 99.1). It specifies that only shareholders of record holding Ordinary Shares (nominal value NIS 0.01) at the close of trading on the Nasdaq Global Market on October 2, 2014, are entitled to vote. No specific business outlook, management commentary on operations, or risk factors are detailed in the provided text.
Key Facts for Investor Verification
- Verify the specific agenda items and proposals contained in the attached Proxy Statement (Exhibit 99.1) for the October 30, 2014 meeting.
- Confirm the record date of October 2, 2014, to determine voting eligibility.
- Note that the registrant files annual reports under Form 20-F.
- Identify that the registrant is not furnishing information pursuant to Rule 12g3-2(b).